Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects - PubMed (original) (raw)
Review
. 2001 Feb 21;93(4):266-76.
doi: 10.1093/jnci/93.4.266.
Affiliations
- PMID: 11181773
- DOI: 10.1093/jnci/93.4.266
Review
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects
M Höckel et al. J Natl Cancer Inst. 2001.
Abstract
Tissue hypoxia results from an inadequate supply of oxygen (O(2)) that compromises biologic functions. Evidence from experimental and clinical studies increasingly points to a fundamental role for hypoxia in solid tumors. Hypoxia in tumors is primarily a pathophysiologic consequence of structurally and functionally disturbed microcirculation and the deterioration of diffusion conditions. Tumor hypoxia appears to be strongly associated with tumor propagation, malignant progression, and resistance to therapy, and it has thus become a central issue in tumor physiology and cancer treatment. Biochemists and clinicians (as well as physiologists) define hypoxia differently; biochemists define it as O(2)-limited electron transport, and physiologists and clinicians define it as a state of reduced O(2) availability or decreased O(2) partial pressure that restricts or even abolishes functions of organs, tissues, or cells. Because malignant tumors no longer execute functions necessary for homeostasis (such as the production of adequate amounts of adenosine triphosphate), the physiology-based definitions of the term "hypoxia" are not necessarily valid for malignant tumors. Instead, alternative definitions based on clinical, biologic, and molecular effects that are observed at O(2) partial pressures below a critical level have to be applied.
Similar articles
- Biological consequences of tumor hypoxia.
Höckel M, Vaupel P. Höckel M, et al. Semin Oncol. 2001 Apr;28(2 Suppl 8):36-41. Semin Oncol. 2001. PMID: 11395851 Review. - Tumor oxygenation: an appraisal of past and present concepts and a look into the future : Arisztid G. B. Kovách Lecture.
Vaupel P. Vaupel P. Adv Exp Med Biol. 2013;789:229-236. doi: 10.1007/978-1-4614-7411-1_31. Adv Exp Med Biol. 2013. PMID: 23852499 - Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response.
Vaupel P, Harrison L. Vaupel P, et al. Oncologist. 2004;9 Suppl 5:4-9. doi: 10.1634/theoncologist.9-90005-4. Oncologist. 2004. PMID: 15591417 Review. - Implications of Oxygen Homeostasis for Tumor Biology and Treatment.
Garvalov BK, Acker T. Garvalov BK, et al. Adv Exp Med Biol. 2016;903:169-85. doi: 10.1007/978-1-4899-7678-9_12. Adv Exp Med Biol. 2016. PMID: 27343096 Review. - Clinical and Pre-clinical Methods for Quantifying Tumor Hypoxia.
Rickard AG, Palmer GM, Dewhirst MW. Rickard AG, et al. Adv Exp Med Biol. 2019;1136:19-41. doi: 10.1007/978-3-030-12734-3_2. Adv Exp Med Biol. 2019. PMID: 31201714 Review.
Cited by
- Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies.
Ciepła J, Smolarczyk R. Ciepła J, et al. Clin Exp Med. 2024 Oct 3;24(1):235. doi: 10.1007/s10238-024-01501-1. Clin Exp Med. 2024. PMID: 39361163 Free PMC article. Review. - Impact of elevated IOP on lamina cribrosa oxygenation; A combined experimental-computational study on monkeys.
Lu Y, Hua Y, Wang B, Zhong F, Theophanous A, Tahir S, Lee PY, Sigal IA. Lu Y, et al. bioRxiv [Preprint]. 2024 Sep 10:2024.09.05.609208. doi: 10.1101/2024.09.05.609208. bioRxiv. 2024. PMID: 39314421 Free PMC article. Preprint. - NF-κB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironment.
de la Calle-Fabregat C, Calafell-Segura J, Gardet M, Dunsmore G, Mulder K, Ciudad L, Silvin A, Moreno-Càceres J, Corbí ÁL, Muñoz-Pinedo C, Michels J, Gouy S, Dutertre CA, Rodríguez-Ubreva J, Ginhoux F, Ballestar E. de la Calle-Fabregat C, et al. Sci Adv. 2024 Sep 20;10(38):eadq5226. doi: 10.1126/sciadv.adq5226. Epub 2024 Sep 18. Sci Adv. 2024. PMID: 39292770 Free PMC article. - Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action.
O'Connor JPB, Tessyman V, Little RA, Babur M, Forster D, Latif A, Cheung S, Lipowska-Bhalla G, Higgins GS, Asselin MC, Parker GJM, Williams KJ. O'Connor JPB, et al. Cancer Res Commun. 2024 Oct 1;4(10):2565-2574. doi: 10.1158/2767-9764.CRC-24-0315. Cancer Res Commun. 2024. PMID: 39240065 Free PMC article. - Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma.
Wang Z, Li Q, Liang B. Wang Z, et al. Pharmaceuticals (Basel). 2024 Aug 11;17(8):1057. doi: 10.3390/ph17081057. Pharmaceuticals (Basel). 2024. PMID: 39204162 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources